Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Supaglutide in T2D suboptimally controlled on metformin
NCT04998032Phase 3Completed
- Sponsor
- Shanghai Innogen Pharmaceutical Technology Co., Ltd.
- Start
- Oct 2021
- Primary completion
- Jun 2023
- Modality
- Peptides, Fc-Fusion Proteins
- Countries
- 1
01
Overview
Phase 3, randomised, double-blind trial of efsubaglutide alfa in type 2 diabetes mellitus (T2DM) (3 arms), sponsored by Shanghai Innogen Pharmaceutical Technology Co., Ltd. Primary endpoint: Glycated Hemoglobin A1c at 52 weeks. Started Oct 2021; status: completed.
02
Drugs
efsubaglutide alfa
03
Conditions
type 2 diabetes mellitus (T2DM)
Beyond the preview
Go deeper on NCT04998032.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04998032.